Expression data from eight patients with coronary heart disease before and after Tongmai Yangxin Pills treatment for eight weeks.

The Tongmai Yangxin Pill (TMYX), a patented medicine, has been widely used to treat coronary heart disease (CHD) in China for several decades. Though the anti-inflammatory effect has been preliminarily proposed as one of the potential mechanisms of TMYX for CHD treatment, the underlying mechanisms remain elusive. We used microarrays to explain the genomic changes of Tongmai Yangxin Pills in the treatment of patients with coronary heart disease, in order to explore the potential mechanism of TCM in the treatment of diseases. Microarray gene expression analysis was used to identify the differentially expressed genes (DEGs) in peripheral blood mononuclear cells of patients before and after TMYX treatment.